|
gptkbp:instanceOf
|
gptkb:drug
biguanide
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
A10BA02
|
|
gptkbp:bioavailability
|
50–60%
|
|
gptkbp:brand
|
gptkb:Riomet
gptkb:Fortamet
gptkb:Glucophage
gptkb:Glumetza
|
|
gptkbp:CASNumber
|
657-24-9
|
|
gptkbp:category
|
antidiabetic medication
hypoglycemic agent
oral antidiabetic drug
|
|
gptkbp:chemicalFormula
|
C4H11N5
|
|
gptkbp:compatibleWith
|
type 1 diabetes
|
|
gptkbp:contraindication
|
gptkb:liver_disease
severe kidney disease
|
|
gptkbp:cost
|
low
|
|
gptkbp:discoveredBy
|
gptkb:James_Bell
gptkb:Emile_Werner
|
|
gptkbp:discoveredIn
|
1922
|
|
gptkbp:effect
|
lowers blood sugar
may reduce cardiovascular risk
weight neutral
|
|
gptkbp:eliminationHalfLife
|
4–8.7 hours
|
|
gptkbp:excretion
|
renal
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
metformin
|
|
gptkbp:introducedIn
|
1957
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
decreases hepatic glucose production
increases insulin sensitivity
|
|
gptkbp:meltingPoint
|
223–226 °C
|
|
gptkbp:metabolism
|
not metabolized
|
|
gptkbp:molecularWeight
|
129.164 g/mol
|
|
gptkbp:origin
|
derived from Galega officinalis (French lilac)
|
|
gptkbp:overdoseSymptoms
|
lactic acidosis
|
|
gptkbp:pregnancyCategory
|
B (US)
B3 (Australia)
|
|
gptkbp:prescribes
|
adults
children over 10 years
|
|
gptkbp:proteinBinding
|
negligible
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL1431
4091
3947
DB00331
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
gastrointestinal upset
lactic acidosis
|
|
gptkbp:solubility
|
water soluble
|
|
gptkbp:UNII
|
9100L32L2N
|
|
gptkbp:usedFor
|
gptkb:polycystic_ovary_syndrome
gptkb:type_2_diabetes
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
true
|
|
gptkbp:bfsParent
|
gptkb:polycystic_ovary_syndrome
gptkb:Type_2_diabetes
|
|
gptkbp:bfsLayer
|
5
|